Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HITSOVA: Danaparoid vs Argatroban in Acute Heparin-Induced Thrombocytopenia
2018-002473-21Phase 3Terminated
- Sponsor
- Aspen Global Incorporated
- Start
- Sep 2018
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of danaparoid sodium in heparin-induced thrombocytopenia (HIT) (2 arms), sponsored by Aspen Global Incorporated. Primary endpoint: Treatment response at Day 44 (composite primary efficacy endpoint). Started Sep 2018; status: terminated.
02
Drugs
danaparoid sodium
03
Conditions
heparin-induced thrombocytopenia (HIT)
Beyond the preview
Go deeper on 2018-002473-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002473-21.